Drug Profile
Leronlimab - CytoDyn
Alternative Names: Leronlimab-PRO 140; leronlimab-PRO140; PA-14; PRO-140; Vyrologix®Latest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator Progenics Pharmaceuticals
- Developer Albert Einstein Israelite Hospital; CytoDyn; Progenics Pharmaceuticals
- Class Antineoplastics; Antiretrovirals; Antivirals; Hepatoprotectants; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action CCR5 receptor antagonists; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Triple negative breast cancer
- Preregistration COVID 2019 infections; HIV infections
- Phase III COVID-19 pneumonia
- Phase II Graft-versus-host disease; Non-alcoholic steatohepatitis; Post acute COVID 19 syndrome; Solid tumours
- Preclinical Multiple sclerosis; Stroke; Traumatic brain injuries
- Discontinued HIV-1 infections
Most Recent Events
- 29 Feb 2024 U.S. FDA has lifted the clinical hold on the a pre-exposure prophylaxis (PrEP) clinical trial of Leronlimab in HIV infections
- 06 Feb 2024 Cytodyn in partnership with Albert Einstein College of Medicine and Montefiore Medical Center plans a preclinical trial for Glioblastoma in USA in 2024
- 01 Feb 2024 Cytodyn in collaboration with Albert Einstein College of Medicine has submitted its revised HIV clinical trial protocol to the FDA